Entera Bio Ltd.
ENTX
$2.17
-$0.12-5.24%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 607.14% | 159.09% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 607.14% | 159.09% | -- | -- |
| Cost of Revenue | -- | 1,025.00% | 242.86% | -- | -- |
| Gross Profit | -- | 50.00% | 12.50% | -- | -- |
| SG&A Expenses | 15.01% | -12.79% | -27.45% | -34.68% | -42.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 82.46% | 56.86% | 29.41% | 2.00% |
| Total Operating Expenses | 9.84% | -11.05% | -21.19% | -25.40% | -33.69% |
| Operating Income | -7.81% | 11.88% | 21.55% | 24.98% | 33.02% |
| Income Before Tax | -7.53% | 7.72% | 18.74% | 23.35% | 31.50% |
| Income Tax Expenses | -51.72% | 100.00% | -80.41% | -79.86% | -78.83% |
| Earnings from Continuing Operations | -7.33% | 7.56% | 19.60% | 24.06% | 31.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.33% | 7.56% | 19.60% | 24.06% | 31.99% |
| EBIT | -7.81% | 11.88% | 21.55% | 24.98% | 33.02% |
| EBITDA | -7.97% | 11.84% | 21.58% | 25.05% | 33.12% |
| EPS Basic | 17.41% | 24.43% | 28.71% | 28.31% | 32.42% |
| Normalized Basic EPS | 17.23% | 27.91% | 31.01% | 29.28% | 33.26% |
| EPS Diluted | 17.41% | 24.43% | 29.38% | 28.94% | 32.93% |
| Normalized Diluted EPS | 17.23% | 27.91% | 31.01% | 29.28% | 33.26% |
| Average Basic Shares Outstanding | 29.78% | 22.40% | 14.74% | 7.57% | 0.69% |
| Average Diluted Shares Outstanding | 29.78% | 22.40% | 14.74% | 7.57% | 0.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |